The initial success of Sildenafil undeniably reshaped the drug landscape, but investing in companies primarily reliant on off-patent versions presents a uncertain picture. Despite early earnings were substantial, the cessation of patents and the emergence of less expensive alternatives have weakened the customer base. Thus, a thorough evaluation of